ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Rapport
Vertraagde tijd Nasdaq  -  27/05 22:00:00 CEST
48.64 USD   +6.11%
24/05ULTRAGENYX PHARMACEUTICAL INC. : Goldman Sachs is neutraal gestemd over het aandeel
MM
19/05ULTRAGENYX PHARMACEUTICAL INC. : Piper Sandler bevestigt koopadvies
MM
19/05Ultragenyx Pharmaceutical Inc. Kondigt positieve gegevens aan over de duurzaamheid op langere termijn van twee fase 1/2-onderzoeken naar gentherapie
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ULTRAGENYX PHARMACEUTICAL INC.
19/05Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
GL
19/05Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
AQ
17/05ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
17/05Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
17/05Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
AQ
09/05Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
GL
09/05Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
AQ
06/05ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
05/05ULTRAGENYX : Q1 Earnings Snapshot
AQ
05/05Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
GL
05/05Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
AQ
03/05Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
03/05Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
03/05Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
GL
27/04Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
GL
27/04Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
GL
25/04Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
GL
25/04Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
GL
22/04ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K)
AQ
22/04Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
AQ
21/04Mereo's Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical ..
AQ
20/04Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusu..
AQ
02/03Ultragenyx to Participate in the Cowen Health Care Conference
AQ
15/02ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
12/02ULTRAGENYX : Q4 Earnings Snapshot
AQ
10/02ULTRAGENYX PHARMACEUTICAL : Reports Fourth Quarter and Full Year 2021 Financial Results an..
PU
10/02Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Up..
AQ
03/02Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Resu..
AQ
03/02Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
02/02Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
02/02Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/01Ultragenyx reports preliminary 2021 revenue and 2022 revenue guidance for crysvita in u..
AQ
11/01Ultragenyx reports preliminary 2021 revenue and 2022 revenue guidance for crysvita in u..
AQ
10/01Regeneron and ultragenyx collaborate to commercialize evkeeza (evinacumab) outside the ..
AQ
10/01ULTRAGENYX PHARMACEUTICAL : REPORTS PRELIMINARY 2021 REVENUE AND 2022 REVENUE GUIDANCE FOR..
PU
10/01ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, Regulation..
AQ
10/01Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvitaģ in ..
AQ
07/01ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
07/01ULTRAGENYX PHARMACEUTICAL : Evkeeza is a first-in-class medicine approved by the U.S. Food..
PU
06/01Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference
AQ
05/01GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102..
AQ
03/01Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference
AQ
2021Genetx and ultragenyx announce presentations at upcoming 2021 fast global summit & gala
AQ
2021GeneTx and Ultragenyx†Announce Presentations at Upcoming†2021 FAST Global Summit & Gala
GL
2021Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA ..
AQ
2021Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
GL
2021Ultragenyx to Present at Evercore 4th Annual HealthconX Conference
GL
2021Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV ..
AQ
2021ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
AQ
2021Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update - Form 8-K
PU
2021ULTRAGENYX : Q3 Earnings Snapshot
AQ
2021Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update
AQ
2021Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corpora..
AQ
2021ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy/Editing Summit
GL
2021ULTRAGENYX PHARMACEUTICAL : Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 ..
AQ
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce First Patient Dosed in Canada i..
PU
2021ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce First Patient Dosed in Canada i..
AQ
2021ULTRAGENYX PHARMACEUTICAL : Reports inducement grant under nasdaq listing rule 5635(4)
AQ
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2021Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
2021ULTRAGENYX PHARMACEUTICAL : Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ..
AQ
2021ULTRAGENYX PHARMACEUTICAL : Announces Crysvitaģ (burosumab) and UX143 (setrusumab) Data Pr..
GL
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold o..
PU
2021ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
2021ULTRAGENYX PHARMACEUTICAL : GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold o..
AQ
2021MEDIA ADVISORY : Ultragenyx Announces Mepseviiģ (vestronidase alfa) Receives Reimbursement..
AQ
2021Ultragenyx to Present at Morgan Stanley Healthcare Conference
GL
2021MEDIA ADVISORY : Ultragenyx Canada Announces Health Canada Approval of a Second Indication..
AQ
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
AQ
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
AQ
2021Ultragenyx Announces Approval of Dojolviģ (triheptanoin) in Brazil for the Treatment of..
GL
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
2021ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
2021ULTRAGENYX PHARMACEUTICAL : to Participate in Gene Therapy Panel at Wedbush PacGrow Health..
AQ
1  2  3  4  5  6  7Volgende
Volgende evenement op ULTRAGENYX PHARMACEUTICAL INC.